Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

Present status of serum markers.

Minton JP, Chevinsky A.

Semin Surg Oncol. 1989;5(6):426-35. Review.

PMID:
2688032
2.

Tumor markers.

Seleznick MJ.

Prim Care. 1992 Dec;19(4):715-26. Review.

PMID:
1281552
3.

Serum CEA, CA 15-3, and MCA in breast cancer patients: a clinical evaluation.

Repetto L, Onetto M, Gardin G, Costanzi B, Giudici S, Vitiello E, Merlini L, Naso C, Zannini C, Paganuzzi M, et al.

Cancer Detect Prev. 1993;17(3):411-5.

PMID:
8402728
4.

Detection of occult metastatic breast cancer cells in blood by a multimolecular marker assay: correlation with clinical stage of disease.

Taback B, Chan AD, Kuo CT, Bostick PJ, Wang HJ, Giuliano AE, Hoon DS.

Cancer Res. 2001 Dec 15;61(24):8845-50.

5.

Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE.

Ebert W, Hoppe M, Muley T, Drings P.

Anticancer Res. 1997 Jul-Aug;17(4B):2875-8.

PMID:
9329552
6.

[Clinical usefulness of tumor markers in breast cancer].

Konishi K, Karaki K, Watanabe K, Tsuda H, Konishi F.

Rinsho Byori. 1993 Oct;41(10):1108-15. Japanese.

PMID:
8254956
7.

[Clinical usefulness of a new tumor marker CYFRA21-1 in patients with lung cancer].

Li R, Li R, Wang Y.

Zhonghua Jie He He Hu Xi Za Zhi. 1998 Jan;21(1):26-9. Chinese.

PMID:
11263296
8.

[Tumor markers. Their current diagnostic status].

Kudlacek S.

Wien Med Wochenschr. 1988 May 31;138(10):228-42. Review. German.

PMID:
3043919
9.

Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the Diagnosis of primary colorectal cancer and at its relapse.

Nicolini A, Caciagli M, Zampieri F, Ciampalini G, Carpi A, Spisni R, Colizzi C.

Cancer Detect Prev. 1995;19(2):183-95.

PMID:
7750106
10.

[Cytokeratin tumor markers in ovarian carcinoma: tissue polypeptide specific antigen (TPS) and M3/M21].

Hefler L, Tempfer C, Häusler G, Heinzl H, Kainz C.

Wien Klin Wochenschr. 1998 Oct 2;110(18):635-41. German.

PMID:
9816636
11.

The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature.

Gadducci A, Tana R, Cosio S, Genazzani AR.

Crit Rev Oncol Hematol. 2008 Apr;66(1):10-20. Epub 2007 Oct 26. Review.

PMID:
17964182
12.
13.

[Considerations in rational use of tumor markers in breast carcinoma].

Crombach G.

Praxis (Bern 1994). 1998 Apr 22;87(17):589-94. Review. German.

PMID:
9623326
14.

CA 125, NB/70K, and lipid-associated sialic acid in monitoring uterine papillary serous carcinoma.

Tseng PC, Sprance HE, Carcangiu ML, Chambers JT, Schwartz PE.

Obstet Gynecol. 1989 Sep;74(3 Pt 1):384-7.

PMID:
2761916
15.

Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process?

Ebert W, Muley T, Drings P.

Anticancer Res. 1996 Jul-Aug;16(4B):2161-8. Review.

PMID:
8694537
16.

Implications of prognostic markers in brain tumors.

Grzybicki DM, Moore SA.

Clin Lab Med. 1999 Dec;19(4):833-47. Review.

PMID:
10572718
17.

Serum tumor markers in patients with breast cancer.

Lumachi F, Basso SM.

Expert Rev Anticancer Ther. 2004 Oct;4(5):921-31. Review.

PMID:
15485325
18.

[The role of tumor markers in lung cancer management].

Ariyoshi Y, Kuwabara M.

Gan To Kagaku Ryoho. 1987 Nov;14(11):3020-6. Japanese.

PMID:
2823721
19.

Clinical usage of the squamous cell carcinoma antigen in patients with penile cancer.

Touloupidis S, Zisimopoulos A, Giannakopoulos S, Papatsoris AG, Kalaitzis C, Thanos A.

Int J Urol. 2007 Feb;14(2):174-6.

20.

MCA performance in preoperative breast cancer patients.

Donadeo A, Micelli G, Quaranta M, Atlante A, Schittulli F.

Anticancer Res. 1995 Mar-Apr;15(2):527-9.

PMID:
7763034

Supplemental Content

Support Center